According to the latest National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 3.2024—February 12, 2024) [11], genetic testing for PALB2 variants, along with BRCA1/2, is recommended for patients with suspected hereditary breast, ovarian, or pancreatic cancer. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.